BCM
NKTR icon

Bronte Capital Management’s Nektar Therapeutics NKTR Stock Holding History

Bronte Capital Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-202,500
Closed -$14.6M – 64
2026
Q1 		$14.6M Buy
+202,500
New +$11.5M 1.44% 15

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bronte Capital Management's NKTR Position: Q2 2026 in Review

Bronte Capital Management increased its Nektar Therapeutics (NKTR) stake by 0.09% in Q2 2026, buying an estimated $13K and bringing the position to 198,434 shares worth $13.9M. The position accounts for 1.49% of the portfolio, ranked #17.

Bronte Capital Management first reported a position in NKTR in Q1 2026 and has held it in 2 quarters since. The position peaked at $14.3M in Q1 2026. 239 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Bronte Capital Management held 198,434 shares of Nektar Therapeutics worth $13.9M as of Q2 2026.
  • Bronte Capital Management bought 178 Nektar Therapeutics shares in Q2 2026, an estimated $13K.
  • Nektar Therapeutics made up 1.49% of Bronte Capital Management's portfolio in Q2 2026, its #17 holding.
  • Bronte Capital Management first reported a position in Nektar Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Bronte Capital Management's Nektar Therapeutics position peaked at $14.3M in Q1 2026.
  • 239 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Bronte Capital Management's 13F filing for Q2 2026, filed 5 Aug 2026.